<DOC>
	<DOCNO>NCT00457405</DOCNO>
	<brief_summary>This study perform determine whether seven day treatment dipyridamole ( slow release , 200mg twice daily ) induce protective effect ischemia-reperfusion injury , ischemic exercise non-dominant forearm healthy volunteer .</brief_summary>
	<brief_title>Does Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury ?</brief_title>
	<detailed_description>Rationale : Dipyridamole increase endogenous adenosine level inhibition nucleoside transporter ( ENT-1 ) . Activation adenosine receptor protect ischemia-reperfusion injury ( pharmacologic preconditioning ) . The purpose project explore whether seven day treatment dipyridamole reduce ischemia-reperfusion injury forearm , randomize double blind placebo control trial . Study design : Randomized double-blind placebo-controlled trial cross-over design . Study population : Healthy male volunteer , age 18-50 yr Intervention : 10 Volunteers randomise receive cross-over design either 7 day treatment dipyridamole ( Persantin retard ; 200 mg twice daily ) placebo follow 10 minute ischemic isometric muscle contraction non-dominant forearm upon reperfusion infusion radiolabeled Annexin A5 ( Annexin scintigraphy ) . Main study parameters/endpoints : Percentage difference radioactivity ( counts/pixel ) experimental control thenar muscle 60 240 minute reperfusion . Nature extent burden risk associate participation , benefit group relatedness : This study execute Clinical Research Centre Nijmegen close medical supervision . Treatment dipyridamole expect harm volunteer . During first day treatment dipyridamole , headache may occur . Ischemic hand grip temporarily result pain forearm . This completely reversible upon reperfusion . Administration radiolabeled Annexin A5 result effective dose less 5 mSv , well within range accept exposure radioactivity human research . Participation research interfere possible diagnostic therapeutic procedure X-rays radioactivity future . Occurrence allergic reaction theoretically possible upon administration Annexin A5 , however allergic reaction report volunteer expose Annexin A5 . The volunteer benefit directly participate study .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Reperfusion Injury</mesh_term>
	<mesh_term>Dipyridamole</mesh_term>
	<criteria>Male age 1850yr . cardiovascular disease hypertension ( systole &gt; 140 mmHg , diastole &gt; 90 mmHg ) hypercholesterolemia ( fast total cholesterol &gt; 5.5 mmol/l fast total cholesterol &gt; 6.5mmol/L ) diabetes mellitus ( fast glucose &gt; 7.0 mmol/L random glucose &gt; 11.0 mmol/L ) asthma ( recurrent episode dyspnea wheezing , usage prescribe inhalation medication : i.e . corticosteroid B2agonists ) participation clinical trial last 60 day prior study . administration radioactivity research purpose last 5 year prior study . concomitant medication</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>ischemia-reperfusion injury</keyword>
	<keyword>atherosclerosis</keyword>
	<keyword>dipyridamole</keyword>
	<keyword>annexin A5 target</keyword>
</DOC>